Epics Therapeutics Initiates First-in-Human Studies with EP282, an oral Investigational Drug for the treatment of gastrointestinal inflammatory disorders and cancer.

January 12th, 2022 – Epics…

Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform

Confo Therapeutics Expands Patent Estate…

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

- Unblinded Data Established a…

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

NEW YORK, Dec. 9, 2021…

ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors

ONA Therapeutics Appoints Dr Michel…

Confo Therapeutics Enters Collaborative Agreement with Regeneron

Confo Therapeutics Enters Collaborative Agreement…

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

NEW YORK, Nov. 18, 2021…

Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity

– Fully Enrolled Phase 2…

Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

Presentation highlights reduction in cerebral…

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Novadip Biosciences announces EUR 19…